Indiana is set to receive $5.4 million of a $125 million dollar settlement against a drug company that was found guilty of engaging in anti-competitive conduct.
The suit found Cephalon intentionally defrauded the Patent Office, filed lawsuits and paid off competitors to delay the release of a generic version of its wakefulness drug Provigil.
$872,000 will be distributed among Indiana consumers.